Solar urticaria successfully treated with intravenous immunoglobulin.
Idiopathic solar urticaria (SU) is a rare, debilitating photodermatosis, which may be difficult to treat. First-line treatment with antihistamines is effective in mild cases, but remission after phototherapeutic induction of tolerance is often short-lived. Other treatment options include plasma exchange, photopheresis and cyclosporin. We present two cases of severe, idiopathic SU, which were resistant to conventional treatment. Both patients achieved remission after administration of intravenous immunoglobulin (IVIg) and have remained in remission at 13 months and 4 years, respectively. There are only two case reports of successful treatment of solar urticaria with IVIg. In our experience IVIg given at a total dose of 2 g/kg over several 5-day courses about a month apart is an effective treatment option for severe idiopathic SU. It is also generally safe, even if certainly subject to significant theoretical risks, such as induction of viral infection or anaphylaxis.
Hughes
R
R
Department of Dermatology, The Adelaide and Meath Hospital, Incorporating the National Children's Hospital Tallaght, Dublin, Ireland.
Cusack
C
C
Murphy
G M
GM
Kirby
B
B
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010787:Photosensitivity Disorders / Q000188:drug therapy* / Q000209:etiology; D013472:Sunlight / Q000009:adverse effects; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000209:etiology
D016756:Immunoglobulins, Intravenous